FrancophonIA/ELRC3.0 huggingface dataset:
English: For the mixed products the onset of immunity is 3 weeks and the duration of immunity is 8 weeks for the claimed protection against Massachusetts and QX-like strains of IBV.
Estonian: Segatud ravimite puhul kujuneb immuunsus välja 3 nädalaga ja immuunsuse kestus väidetavaks kaitseks IBV Massachussetsi ja QX-i laadsete variantide suhtes on 8 nädalat.
English: Sealed aluminium laminate cup with a polypropylene (cup) and polypropylene/polyethylene (lid) contact layer containing 1,000; 2,500; 5,000 or 10,000 doses.
Estonian: Suletud alumiinium laminaat tops, millel on polüpropüleenist (tops) ja polüpropüleenist/polüetüleenist (kaas) kontaktkiht ning mis sisaldab 1000, 2500, 5000 või 10 000 annust.
English: Solvent (Solvent Oculo/Nasal): blue-coloured solution.
Estonian: Lahusti (Solvent Oculo/Nasal): sinist värvi lahus.
English: 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Estonian: 6.6 Erinõuded ettevaatusabinõude osas kasutamata jäänud veterinaarravimite või nende kasutamisest tekkinud jäätmete hävitamisel
English: Special precautions for use in animals: All chickens on the site should be vaccinated at the same time.
Estonian: Ettevaatusabinõud kasutamisel loomadel Kõik koospeetavad kanad tuleb vaktsineerida samaaegselt.
English: NAME OF THE VETERINARY PRODUCT
Estonian: VETERINAARTOOTE NIMETUS
English: Sodium hydroxide or hydrochloric acid (for pH adjustment) Water for injections
Estonian: Naatriumhüdroksiid või vesinikkloriidhape (pH reguleerimiseks) Süstevesi
English: It is important to avoid introduction of the IB D388 vaccine virus into premises in which the wild type strain is not present.
Estonian: Tähtis on vältida IB D388 vaktsiiniviiruse toomist karjadesse, kus looduslikku viirust ei esine.
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Estonian: A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJAD JA RAVIMIPARTII VABASTAMISE EEST VASTUTAV TOOTJA
English: Read the package leaflet of Nobilis IB Ma5 before use.
Estonian: Lugege Nobilis IB Ma5 ravimi infolehte enne manustamist.
English: 1,000 doses (3-100 spheres) 2,500 doses (3-100 spheres) 5,000 doses (3-100 spheres) 10,000 doses (3-400 spheres)
Estonian: 1000 annust (3-100 kuulikest) 2500 annust (3-100 kuulikest) 5000 annust (3-100 kuulikest) 10 000 annust (3-400 kuulikest)
English: 2) Add the contents of the correct number of cups while stirring.
Estonian: 2) Lisada segades vastava arvu topside sisu.
English: For active immunisation of chickens in order to reduce respiratory signs of avian infectious bronchitis caused by QX-like variants of infectious bronchitis virus (IBV).
Estonian: Kanade aktiivseks immuniseerimiseks vähendamaks infektsioosse bronhiidi viiruse (IBV) QX-i laadsete variantide põhjustatud lindude infektsioosse bronhiidi respiratoorseid haigusnähte.
English: Very mild inflammatory changes have occasionally been found in the kidneys of specific pathogen free (SPF) chickens after administration of a 10-fold overdose.
Estonian: Aeg-ajalt on pärast 10-kordsete üleannuste manustamist spetsiifilisest patogeenist vabade (SPF, specific pathogen free) kanade neerudes leitud väga kergeid põletikulisi muutusi.
English: Cups may contain 3 spheres to up to 400 spheres depending on the required dosages and production yields.
Estonian: Topsid võivad sisaldada 3 kuni 400 vaktsiinikuulikest olenevalt vajatavast annusest ja tootmismahust.
English: CARDBOARD BOX with 10 cups of lyophilisate
Estonian: PAPPKARP 10 topsi lüofilisaadiga
English: To stimulate active immunity against the D388/QX type of avian infectious bronchitis virus.
Estonian: Aktiivse immuunsuste stimuleerimiseks lindude infektsioosse bronhiidi viiruse D388/QX-i tüübi vastu.
English: EU/2/14/174/002 (10 x 1,000 doses + 10 x 35 ml solvent) EU/2/14/174/003 (10 x 5,000 doses)
Estonian: EU/2/14/174/002 (10 x 1000 annust + 10 x 35 ml lahustit) EU/2/14/174/003 (10 x 5000 annust)
English: A mild transient respiratory reaction (including nasal exudates) may very rarely occur for at least 10 days after vaccination.
Estonian: Väga harva võib vähemalt 10 päeva jooksul pärast vaktsineerimist esineda kerge mööduv respiratoorne reaktsioon (kaasa arvatud eksudaadi eritumine ninast).
English: 50% egg infective dose For the full list of excipients, see section 6.1.
Estonian: Abiainete täielik loetelu on esitatud punktis 6.1.
English: Shelf life of the solvent as packaged for sale: 4 years.
Estonian: Müügipakendis lahusti kõlblikkusaeg: 4 aastat.
English: Each dose of reconstituted vaccine contains: Live attenuated avian infectious bronchitis virus, strain D388: 104.0 - 105.5 EID50
Estonian: TOIMEAINE(TE) SISALDUS Elus atenueeritud lindude infektsioosse bronhiidi viiruse tüvi D388: 104,0-105,5 EID50 /annus.
English: Measure the correct volume of water for the number of birds to be vaccinated
Estonian: Mõõta välja vaktsineeritavate lindude arvule vastav veekogus (sõltuvalt kasutatavast seadmest).
English: Solvent: Store below 25 °C.
Estonian: Lahusti: Hoida temperatuuril kuni 25 C.
English: Administer 1 dose of reconstituted vaccine by coarse spray or by oculonasal route to chickens from 1 day of age or older.
Estonian: Manustada 1 annus manustamiskõlblikuks muudetud vaktsiini jämedatilgalise pihusena või okulonasaalsel teel kanadele alates 1. elupäevast ja vanematele.
English: Do not use in birds in lay and within 4 weeks before the start of the laying period.
Estonian: Mitte kasutada munevatel lindudel ja 4 nädala jooksul enne munemisperioodi algust.
English: After reconstitution, administer 1 dose of vaccine by coarse spray or by the oculonasal route of administration to chickens from 1 day of age or older.
Estonian: Pärast manustamiskõlblikuks muutmist, manustada 1 annus vaktsiini jämedatilgalise pihusena või okulonasaalsel teel kanadele alates 1. elupäevast ja vanematele.
English: The IB D388 vaccine should only be applied in hatcheries to chickens from 1 day of age or older if adequate controls are in place to avoid the spread of the vaccine virus to birds that will be transported to non-IB QX exposed flocks.
Estonian: Haudejaamades tohib IBV D388 vaktsiini kasutada ainult kanadel alates 1. elupäevast ja vanematel, kui tarvitusele võetakse piisavad ettevaatusabinõud, et vältida vaktsiiniviiruse levikut lindudele, kes viiakse IBV QX-iga mitte kokkupuutunud karjadesse.
English: A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Estonian: Seetõttu tuleb selle vaktsiini kasutamine otsustada igal erineval juhul eraldi.
English: Do not use in birds in lay or within 4 weeks before the start of the laying period.
Estonian: Mitte kasutada munevatel lindudel ega 4 nädala jooksul enne munemisperioodi algust.
English: Ensure that the nasal drop is inhaled before freeing the bird.
Estonian: Enne linnu vabastamist tuleb veenduda, et ninaavasse manustatud tilk oleks sisse hingatud.
English: Lyophilisate: Off white, predominantly sphere shaped.
Estonian: Lüofilisaat: tuhmvalge, valdavalt kerakujuline.
English: Active substance: Live attenuated avian infectious bronchitis virus, strain D388: 10
Estonian: Toimeaine: Elus atenueeritud lindude infektsioosse bronhiidi viiruse tüve D388: 10
English: Cardboard box with 10 cups of lyophilisate (1,000 doses per 42 mm diameter cup (3-100 spheres)) + cardboard box with 10 x 35 ml vial of solvent supplemented with dropper and adapter.
Estonian: Pappkarp 10 topsiga, milles on lüofilisaat (10 000 annust 42 mm läbimõõduga topsi kohta (3-100 kuulikest)) + pappkarp 10 x 35 ml lahusti viaaliga, millele on lisatud pipett ja adapter.
English: Solvent (Solvent Oculo/Nasal):
Estonian: Lahusti (Solvent Oculo/Nasal)
English: Solvent for oculonasal suspension.
Estonian: Okulonasaalse suspensiooni lahusti.
English: Spray or oculonasal administration.
Estonian: Pihustamise teel või okulonasaalselt.
English: Lyophilisate for oculonasal suspension
Estonian: Okulonasaalse suspensiooni lüofilisaat.
English: CARDBOARD BOX with 10 vials of solvent
Estonian: PAPPKARP 10 viaali lahustiga
English: Hydrolysed gelatine Pancreatic digest of casein Disodium phosphate dihydrate
Estonian: Hüdrolüüsitud želatiin Pankrease ensüümidega töödeldud kaseiin Dinaatriumfosfaatdihüdraat
English: Read the vaccine package before use.
Estonian: Enne ravimi kasutamist lugege pakendi infolehte.
English: Solvent Oculo/Nasal for chickens
Estonian: Solvent Oculo/Nasal, kanadele
English: EU/2/14/174/005 (10 x 2,500 doses)
Estonian: EU/2/14/174/005 (10 x 2500 annust)
English: Chickens
Estonian: Hipaania
English: PARTICULARS TO APPEAR ON IMMEDIATE PACKAGING
Estonian: ANDMED, MIS PEAVAD OLEMA VAHETUL SISEPAKENDIL
English: See package leaflet.
Estonian: Vaata pakendi infolehte.
English: Nobilis IB Primo QX lyophilisate for oculonasal suspension for chickens
Estonian: Nobilis IB Primo QX, okulonasaalse suspensiooni lüofilisaat kanadele
English: EU/2/14/174/004 (10 x 10,000 doses)
Estonian: EU/2/14/174/004 (10 x 10 000 annust)
English: PACKAGE LEAFLET: Nobilis IB Primo QX lyophilisate and solvent for oculonasal suspension for chickens Nobilis IB Primo QX lyophilisate for oculonasal suspension for chickens
Estonian: PAKENDI INFOLEHT Nobilis IB Primo QX, okulonasaalse suspensiooni lüofilisaat ja lahusti, kanadele Nobilis IB Primo QX, okulonasaalse suspensiooni lüofilisaat, kanadele
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Estonian: TOIMEAINETE JA ABIAINETE SISALDUS
English: EU/2/14/174/001 (10 x 1,000 doses)
Estonian: EU/2/14/174/001 (10 x 1000 annust)
English: Nobilis IB Primo QX lyophilisate and solvent for oculonasal suspension for chickens Nobilis IB Primo QX lyophilisate for oculonasal suspension for chickens
Estonian: Nobilis IB Primo QX, okulonasaalse suspensiooni lüofilisaat ja lahusti kanadele Nobilis IB Primo QX, okulonasaalse suspensiooni lüofilisaat kanadele
English: Lyophilisate and solvent for oculonasal suspension Lyophilisate for oculonasal suspension.
Estonian: Okulonasaalse suspensiooni lüofilisaat ja lahusti.
English: Solvent Oculo/Nasal is available as solvent for oculonasal application.
Estonian: Okulonasaalse manustamise jaoks on saadaval lahusti Solvent Oculo/Nasal.
English: Cardboard box with 10 cups of lyophilisate (10,000 doses per 61 mm diameter cup (3-400 spheres)).
Estonian: Pappkarp 10 topsiga, milles on lüofilisaat (10 000 annust 61 mm läbimõõduga topsi kohta (3-400 kuulikest)).
English: Live attenuated avian infectious bronchitis virus, strain D388: 10
Estonian: Iga annus manustamiskõlblikuks muudetud vaktsiini sisaldab: Elus atenueeritud lindude infektsioosse bronhiidi viiruse tüve D388: 10
English: Packaging:
Estonian: Manustamisviisid
English: Cardboard box with 10 cups of lyophilisate (1,000 doses per 42 mm diameter cup (3-100 spheres)).
Estonian: Pappkarp 10 topsiga, milles on lüofilisaat (1000 annust 42 mm läbimõõduga topsi kohta (3-100 kuulikest)).
English: Solvent Oculo/Nasal should be used for oculonasal application.
Estonian: Okulonasaalse manustamise puhul peab kasutama lahustit Solvent Oculo/Nasal.
English: Name and address of the manufacturer responsible for batch release
Estonian: Ravimipartii vabastamise eest vastutava tootja nimi ja aadress intervet International B.V.
English: Cardboard box with 10 cups of lyophilisate (2,500 doses per 42 mm diameter cup (3-100 spheres)).
Estonian: Pappkarp 10 topsiga, milles on lüofilisaat (2500 annust 42 mm läbimõõduga topsi kohta (3-100 kuulikest)).
English: Cardboard box with 10 cups of lyophilisate (5,000 doses per 42 mm diameter cup (3-100 spheres)).
Estonian: Pappkarp 10 topsiga, milles on lüofilisaat (5000 annust 42 mm läbimõõduga topsi kohta (3-100 kuulikest)).
English: Incompatibilities:
Estonian: Sobimatus
English: LABEL - Solvent VIALS
Estonian: ETIKETT - lahusti VIAALID
English: --1 ≥ 3.2 x 10
Estonian: --1 ≥ 3,2 × 106 ELISA ühikut
English: EU number
Estonian: EL number
English: Packaging Content Package size
Estonian: Manustamisviis Pakend Sisaldus Pakendi suurus
English: Strength Pharmaceutical form
Estonian: Ravimvorm Loomaliigid
English: Invented name
Estonian: Nimetus Tugevus
English: It can be found here (in English only).
Estonian: See dokument on kättesaadav siin (ainult inglise keeles).
English: Summary of product characteristics 4.8.
Estonian: Ravimi omaduste kokkuvõte 4.8.
English: Current text to be deleted is struck through.
Estonian: Praegune tekst, mis jäetakse välja, on läbi kriipsutatud.
English: Uncommon Rare Not known
Estonian: Aeg-ajalt Harv Teadmata
English: Common side effects (may affect up to 1 in 10 people) - Collection of fluid around the heart (pericardial effusion)
Estonian: Sageli esinevad kõrvaltoimed (võivad tekkida kuni 1 inimesel 10st): - vedeliku kogunemine südame ümber (perikardiaalne efusioon)
English: Propofol; valproate - Pharmacokinetic drug interaction leading to an increased propofol exposure (EPITT no 18696)
Estonian: Propofool; valproaat - farmakokineetiline ravimi koostoime, mis suurendab kokkupuudet propofooliga (EPITT nr 18696)
English: When used concomitantly, a dose reduction of propofol may be considered.
Estonian: Neid ravimeid koos kasutades tuleks kaaluda propofooli annuse vähendamist.
English: Adopted at the 9-12 January 2017 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 9.-12. jaanuari 2017. aasta koosolekul
English: The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals' which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals.
Estonian: Käesolevas dokumendis on ravimiteabe sõnastus võetud dokumendist „Ravimiohutuse riskihindamise komitee soovitused ohusignaalide põhjal”, mis sisaldab ravimiohutuse riskihindamise komitee soovituste täisteksti ravimiteabe ajakohastamise kohta ja üldisi suuniseid, kuidas tegutseda ohusignaalide korral.
English: Interaction with other medicinal products and other forms of interaction A need for lower propofol doses has been observed in patients taking valproate.
Estonian: Koostoimed teiste ravimitega ja muud koostoimed On täheldatud, et valproaati võtvad patsiendid vajavad propofooli väiksemaid annuseid.
English: Azacitidine - Pericarditis and pericardial effusion (EPITT no 18733)
Estonian: Asatsitidiin - perikardiit ja perikardiaalne efusioon (EPITT nr 18733)
English: Undesirable effects Tabulated list of adverse reactions System Organ
Estonian: Kõrvaltoimed Kõrvaltoimete tabel Organsüsteemi klass
English: Pericardial effusion
Estonian: Perikardiaalne efusioon
English: New text to be added to the product information is underlined.
Estonian: Ravimiteabesse lisatav uus tekst on alla joonitud.
English: Very common
Estonian: Väga sage Sage
English: Summary of product characteristics (propofol) 4.5.
Estonian: Ravimi omaduste kokkuvõte (propofool)
English: D-55127 Mainz
Estonian: D-55127 Mainz Saksamaa
English: 1010 Wien Austria
Estonian: 1010 Wien
English: Flemingweg 18, 2408 AV ALPHEN A/D RIJN The Netherlands
Estonian: Flemingweg 18, 2408 AV ALPHEN A/D RIJN Holland
English: Quinta da Fonte - Edifício D. José - Piso 1, 2780-730 Paço d' Arcos
Estonian: Quinta da Fonte - Edifício D. José - Piso 1, 2780730 Paço d' Arcos Portugal
English: Novo Nordisk Limited, Broadfield Park, Brighton Road, Crawley, West Sussex RH11 9RT United Kingdom
Estonian: Ühendkuningriik Novo Nordisk Limited, Broadfield Park, Brighton Road, Crawley, West Sussex RH11 9RT
English: Luxembourg Novo Nordisk Pharma Riverside Business Park B-1070 Bruxelles
Estonian: Luksemburg Novo Nordisk Pharma Riverside Business Park B-1070 Bruxelles
English: Novo Nordisk, Coeur Défense - 100, avenue du Général de Gaulle - 92400 Courbevoie
Estonian: Prantsusmaa Novo Nordisk, Coeur Défense - 100, avenue du Général de Gaulle - 92400
English: List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
Estonian: Lisa I Ravimi(te) nimetuste, ravimvormi(de), tugevus(t)e, manustamisviisi(de), müügiloa hoidja(te) loetelu liikmesriikides
English: Boulevard international 55 1070 Brussels
Estonian: 1070 Brussels Belgia
English: • could become pregnant;
Estonian: • kes võivad rasestuda;
English: The marketing authorisation holder is Daiichi Sankyo Europe GmbH.
Estonian: Müügiloa hoidja on Daiichi Sankyo Europe GmbH.
English: The marketing authorisation was renewed on 5 August 2003 and on 5 August 2008.
Estonian: Müügiluba pikendati 5. augustil 2003 ja 5. augustil 2008.
English: The recommended dose for adults and the elderly is one tablet taken once a day, with or without food.
Estonian: Soovitatav annus täiskasvanutele ja eakatele on üks tablett üks kord ööpäevas, koos toiduga või ilma.
English: It is available as white, oval tablets (60 mg).
Estonian: Seda turustatakse valgete ovaalsete tablettidena (60 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Evista on 5 August 1998.
Estonian: Euroopa Komisjon andis Evista müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 5. augustil 1998.
English: The Committee recommended that Evista be given marketing authorisation.
Estonian: Komitee soovitas anda Evistale müügiloa.
English: What is Evista?
Estonian: Mis on Evista?
English: Evista should not be used in women who:
Estonian: Evistat ei tohi kasutada naised,
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EVISTA EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE EVISTA Kokkuvõte üldsusele
English: The most common side effects with Evista (seen in more than 1 patient in 10) are vasodilation (hot flushes) and flu-like symptoms.
Estonian: Evista kõige sagedamad kõrvalnähud (esinenud enam kui ühel patsiendil kümnest) on vasodilatatsioon (kuumahood) ning gripitaolised sümptomid.
English: The studies measured the density of the bones.
Estonian: Uuringutes mõõdeti luude tihedust.
English: The main measure of effectiveness was how many women had vertebral fractures during the study.
Estonian: Efektiivsuse põhinäitaja oli nende naiste arv, kellel uuringu kestel tekkis lülisambamurd.
English: Why has Evista been approved?
Estonian: Miks Evista heaks kiideti?
English: What is the risk associated with Evista?
Estonian: Mis riskid Evistaga kaasnevad?
English: Evista should not be used in people who may be hypersensitive (allergic) to raloxifene or any of the other ingredients.
Estonian: Evistat ei tohi kasutada patsiendid, kes võivad olla raloksifeeni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Other information about Evista:
Estonian: Muu teave Evista kohta
English: Evista is a medicine containing the active substance raloxifene hydrochloride.
Estonian: Evista on ravim, mis sisaldab toimeainena raloksifeenvesinikkloriidi.
English: For the full list of side effects reported with Evista, see the Package Leaflet.
Estonian: Evista kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: What benefit has Evista shown during the studies?
Estonian: Milles seisneb uuringute põhjal Evista kasulikkus?
English: Evista has been studied in the treatment and the prevention of osteoporosis in four main studies.
Estonian: Evista toimet osteoporoosi ravis ja ennetuses uuriti neljas põhiuuringus.
English: Raloxifene has the same effect as oestrogen in the bone, but it does not have an effect in the breast or the womb.
Estonian: Raloksifeenil on luudes samasugune toime kui östrogeenil, kuid ta ei mõjuta rindu ega emakat.
English: The active substance in Evista, raloxifene, is a selective oestrogen receptor modulator (SERM).
Estonian: Evista toimeaine raloksifeen on selektiivne östrogeeni retseptori modulaator (SERM).
English: • have liver disease, severe kidney disease, unexplained bleeding from the womb or endometrial cancer (cancer of the lining of the womb).
Estonian: • kelle on maksahaigus, raske neeruhaigus, emaka seletamatu veritsemine või endomeetriumi
English: Three studies looked at the prevention of osteoporosis in 1,764 women who took either Evista or placebo (a dummy treatment) for two years.
Estonian: Kolmes osteoporoosi ennetamise uuringus osales 1764 naist, kes võtsid kahe aasta vältel kas Evistat või platseebot (näivat ravimit).
English: Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down.
Estonian: Osteoporoos tekib, kui loomulikul teel lagunenud luuaine asemele ei teki piisavalt uut luud.
English: Over four years, in comparison with placebo, Evista decreased the number of new vertebral fractures by 46% in women who had osteoporosis and by 32% in women who had osteoporosis and an existing fracture.
Estonian: Nelja aasta kestel oli Evista võrreldes platseeboga vähendanud uute lülisambamurdude arvu osteoporoosi põdevatel naistel 46% võrra ning osteoporoosi põdevatel ja eelneva murruga naistel 32% võrra.
English: Evista has been shown to significantly reduce vertebral fractures (breaks in the spine), but not hip fractures.
Estonian: On tõendatud, et Evista vähendab märkimisväärselt lülisambamurde, kuid mitte reieluukaelamurde.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that Evista had shown its effectiveness in preventing and treating osteoporosis, and had no effects on the breast or womb.
Estonian: Inimravimite komitee otsustas, et Evista efektiivsus osteoporoosi ennetamisel ja ravis on tõendatud ning et ravim ei avalda mõju rindadele ega emakale.
English: Gradually, the bones become thin and fragile, and more likely to break (fracture).
Estonian: Sel juhul muutuvad luud urbseks ja hapraks ning võivad kergemini murduda.
English: The fourth study compared the effects of Evista with those of placebo in the treatment of osteoporosis in 7,705 women over four years.
Estonian: Neli aastat kestnud neljandas uuringus võrreldi Evista ja platseebo toimet 7705 naisel osteoporoosi ravis.
English: Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet. Evista is intended for long-term use.
Estonian: Kui patsient ei saa toidust piisavalt kaltsiumi ja D-vitamiini, võib võtta neid sisaldavaid toidulisandeid.
English: In the prevention of osteoporosis, women receiving Evista had an increase in bone density in the hip or spine of 1.6% over two years, and those receiving placebo had a decrease of 0.8%.
Estonian: Osteoporoosi ennetamisel suurenes kahe aasta möödudes Evistat saanud naistel luutihedus lülisambas ja reieluukaelas 1,6%, samas kui platseebot saanud naistel oli luutihedus 0,8% vähenenud.
English: Raloxifene acts as an ‘agonist' of the oestrogen receptor (a substance that stimulates the receptor for oestrogen) in some tissues in the body.
Estonian: Raloksifeen toimib mõnedes organismi kudedes östrogeeni retseptori agonistina (stimuleerib seda retseptorit).
English: When used to treat osteoporosis, Evista was more effective than placebo in reducing the number of vertebral fractures.
Estonian: Osteoporoosi ravis oli Evista lülisambamurdude arvu vähendamisel efektiivsem kui platseebo.
English: • have or have had any blood clot disorders, including deep vein thrombosis and pulmonary embolism (a blood clot in the lungs);
Estonian: • kellel on või on olnud verehüübimishäireid, sealhulgas süvaveenitromboos või kopsuemboolia
English: How is Evista used?
Estonian: Kuidas Evistat kasutatakse?
English: How has Evista been studied?
Estonian: Kuidas Evistat uuriti?
English: The Committee decided that Evista's benefits are greater than its risks for the treatment and prevention of osteoporosis in postmenopausal women.
Estonian: Komitee otsustas, et Evista kasulikkus osteoporoosi ennetamisel ja ravis menopausijärgses eas naistel on suurem kui ravimiga kaasnevad riskid.
English: There was no effect of Evista on hip fractures.
Estonian: Evista kasutamisel puudus toime reieluukaelamurdudele.
English: How does Evista work?
Estonian: Kuidas Evista toimib?
English: The full EPAR for Evista is available here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Evista kohta leiate siit.
English: What is Evista used for?
Estonian: Milleks Evistat kasutatakse?